药物筛选与CRISPR筛选揭示CAR T细胞细胞毒性的关键通路
该研究利用超过500种小分子药物和全基因组CRISPR-Cas9功能缺失筛选,系统探究CAR T细胞细胞毒性的可成药机制。研究发现酪氨酸激酶抑制剂通过损害T细胞信号转录活性抑制CAR T细胞毒性,而SMAC模拟物通过死亡受体信号(FADD、TNFRSF10B)和RIPK1依赖机制增敏B细胞恶性肿瘤对CAR T细胞的杀伤。死亡受体表达随B细胞恶性肿瘤遗传亚型而异,提示其与癌症遗传学相关。
要点
- 酪氨酸激酶抑制剂可抑制CAR T细胞毒性,损害T细胞信号转录活性。
- SMAC模拟物通过死亡受体信号和RIPK1依赖机制增敏CAR T细胞杀伤。
- 死亡受体表达在B细胞恶性肿瘤遗传亚型间存在差异。
核心结论
- 死亡受体信号是癌细胞对CAR T细胞毒性敏感性的重要介质,可作为药理靶点增强免疫治疗。
研究设计与样本
- 研究使用超过500种小分子药物和全基因组CRISPR-Cas9功能缺失筛选,系统探究CAR T细胞细胞毒性的可成药机制。
主要发现
- 多种酪氨酸激酶抑制剂通过损害T细胞信号转录活性抑制CAR T细胞毒性。
- SMAC模拟物使B细胞急性淋巴细胞白血病和弥漫性大B细胞淋巴瘤细胞对anti-CD19 CAR T细胞敏感。
- CRISPR筛选确定通过FADD和TNFRSF10B(TRAIL-R2)的死亡受体信号是CAR T细胞细胞毒性的关键介质,并阐明SMAC模拟物增敏的RIPK1依赖机制。
- 死亡受体表达在B细胞恶性肿瘤不同遗传亚型中存在差异,提示CAR T细胞毒性机制与癌症遗传学相关。
临床怎么用
- 筛选数据提供癌症药物免疫调节特性和影响CAR T细胞毒性的遗传机制资源,可能指导联合用药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refractory B-cell malignancies, but resistance and relapses still occur. Better understanding of mechanisms influencing CAR T-cell cytotoxicity and the potential for modulation using small-molecule drugs could improve current immunotherapies. Here, we systematically investigated druggable mechanisms of CAR T-cell cytotoxicity using >500 small-molecule drugs and genome-scale CRISPR-Cas9 loss-of-function screens. We identified several tyrosine kinase inhibitors that inhibit CAR T-cell cytotoxicity by impairing T-cell signaling transcriptional activity. In contrast, the apoptotic modulator drugs SMAC mimetics sensitized B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma cells to anti-CD19 CAR T cells. CRISPR screens identified death receptor signaling through FADD and TNFRSF10B (TRAIL-R2) as a key mediator of CAR T-cell cytotoxicity and elucidated the RIPK1-dependent mechanism of sensitization by SMAC mimetics. Death receptor expression varied across genetic subtypes of B-cell malignancies, suggesting a link between mechanisms of CAR T-cell cytotoxicity and cancer genetics. These results implicate death receptor signaling as an important mediator of cancer cell sensitivity to CAR T-cell cytotoxicity, with potential for pharmacological targeting to enhance cancer immunotherapy. The screening data provide a resource of immunomodulatory properties of cancer drugs and genetic mechanisms influencing CAR T-cell cytotoxicity.
引用
- Dufva O, Koski J, Maliniemi P, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020. PMID: 31830245. doi:10.1182/blood.2019002121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。